Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DCLD Solicits Comments On Quality Control Portion Of CLIA Waiver Guidance

This article was originally published in The Gray Sheet

Executive Summary

The Center for Devices and Radiological Health is looking to revise the quality control portion of the interim CLIA draft guidance.

You may also be interested in...



CLIA Waiver Authority Shifts To FDA; IVD Office Ready To Test New Methods

CDRH is encouraging manufacturers to work with its in vitro diagnostics office to pilot new ways to meet CLIA waiver criteria

CLIA Waiver Authority Shifts To FDA; IVD Office Ready To Test New Methods

CDRH is encouraging manufacturers to work with its in vitro diagnostics office to pilot new ways to meet CLIA waiver criteria

CLIA Guidance Allows Firms To Gain Waiver Through User Comparison Studies

Manufacturers seeking waived status for diagnostic tests under user-based criteria will need to perform agreement studies with at least 300 untrained users to show that those users obtain the same results as lab professionals, according to an FDA draft guidance issued Jan. 23.

Related Content

UsernamePublicRestriction

Register

MT014800

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel